Momenta Pharmaceuticals, Inc. (MNTA) CEO Sells $165,351.34 in Stock

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler sold 10,406 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $15.89, for a total value of $165,351.34. Following the transaction, the chief executive officer now directly owns 275,526 shares of the company’s stock, valued at $4,378,108.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Craig A. Wheeler also recently made the following trade(s):

  • On Tuesday, November 21st, Craig A. Wheeler sold 4,116 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $13.35, for a total value of $54,948.60.

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) traded up $0.05 on Monday, reaching $16.30. The company’s stock had a trading volume of 571,269 shares, compared to its average volume of 921,225. The firm has a market capitalization of $1,250.00, a P/E ratio of -20.38 and a beta of 1.80. Momenta Pharmaceuticals, Inc. has a 12-month low of $11.85 and a 12-month high of $19.46.

Several equities analysts have recently issued reports on the company. Stifel Nicolaus reiterated a “hold” rating and set a $18.00 price objective on shares of Momenta Pharmaceuticals in a research report on Tuesday, January 30th. BidaskClub downgraded Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 18th. Zacks Investment Research upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. Finally, Cowen set a $15.00 price objective on Momenta Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, November 1st. Two analysts have rated the stock with a sell rating and ten have given a hold rating to the stock. The company has a consensus rating of “Hold” and an average price target of $15.30.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MNTA. Wells Fargo & Company MN lifted its position in Momenta Pharmaceuticals by 6.1% in the second quarter. Wells Fargo & Company MN now owns 205,599 shares of the biotechnology company’s stock worth $3,475,000 after purchasing an additional 11,789 shares during the period. Alliancebernstein L.P. lifted its position in Momenta Pharmaceuticals by 19.5% in the second quarter. Alliancebernstein L.P. now owns 109,296 shares of the biotechnology company’s stock worth $1,847,000 after purchasing an additional 17,800 shares during the period. Nationwide Fund Advisors lifted its position in Momenta Pharmaceuticals by 11.9% in the second quarter. Nationwide Fund Advisors now owns 126,094 shares of the biotechnology company’s stock worth $2,131,000 after purchasing an additional 13,382 shares during the period. New York State Common Retirement Fund lifted its position in Momenta Pharmaceuticals by 9.4% in the second quarter. New York State Common Retirement Fund now owns 286,453 shares of the biotechnology company’s stock worth $4,841,000 after purchasing an additional 24,715 shares during the period. Finally, UBS Asset Management Americas Inc. lifted its position in Momenta Pharmaceuticals by 25.8% in the second quarter. UBS Asset Management Americas Inc. now owns 27,994 shares of the biotechnology company’s stock worth $473,000 after purchasing an additional 5,744 shares during the period. Hedge funds and other institutional investors own 93.01% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Momenta Pharmaceuticals, Inc. (MNTA) CEO Sells $165,351.34 in Stock” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/02/12/momenta-pharmaceuticals-inc-mnta-ceo-sells-165351-34-in-stock.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit